| 15.15 0.31 (2.09%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 20.42 | 1-year : | 23.87 |
| Resists | First : | 17.49 | Second : | 20.44 |
| Pivot price | 15.35  |
|||
| Supports | First : | 12.72 | Second : | 10.58 |
| MAs | MA(5) : | 15.11 |
MA(20) : | 16.21 |
| MA(100) : | 21.81 |
MA(250) : | 26.07 |
|
| MACD | MACD : | -1.2 |
Signal : | -1.3 |
| %K %D | K(14,3) : | 39.2 |
D(3) : | 38.5 |
| RSI | RSI(14): 40.9 |
|||
| 52-week | High : | 34.47 | Low : | 12.72 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IMVT ] has closed above bottom band by 45.5%. Bollinger Bands are 8.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.26 - 15.33 | 15.33 - 15.4 |
| Low: | 14.55 - 14.63 | 14.63 - 14.71 |
| Close: | 15.01 - 15.14 | 15.14 - 15.27 |
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Tue, 08 Apr 2025
Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires? - Insider Monkey
Wed, 19 Mar 2025
Immunovant stock falls despite study success - Investing.com
Wed, 19 Mar 2025
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (IMVT) - Seeking Alpha
Tue, 18 Mar 2025
Immunovant, Inc. to Host Investor Webcast on Phase 3 Study Results of Batoclimab in MG and Phase 2b Study in CIDP - Nasdaq
Tue, 18 Mar 2025
Critical Phase 3 Results: Immunovant's Breakthrough MG and CIDP Treatment Data Reveal Coming Next Week - Stock Titan
Wed, 19 Feb 2025
Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 170 (M) |
| Shares Float | 62 (M) |
| Held by Insiders | 58 (%) |
| Held by Institutions | 49.6 (%) |
| Shares Short | 15,800 (K) |
| Shares Short P.Month | 14,790 (K) |
| EPS | -2.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.39 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -44.8 % |
| Return on Equity (ttm) | -74.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -325 (M) |
| Levered Free Cash Flow | -188 (M) |
| PE Ratio | -5.79 |
| PEG Ratio | 0 |
| Price to Book value | 6.33 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.92 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|